Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04375228 · ClinicalTrials.gov registry record · Phase 2
Study of Rituximab or Tocilizumab for Patients With Steroid-Dependent Immune-Related Adverse Events (irAEs)
A Phase 2 study of Advanced Solid Tumor and Immune Related Adverse Events, sponsored by Columbia University.
- Active
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
- 3
- Study locations
NCT04375228 is a Phase 2 study of Advanced Solid Tumor and Immune Related Adverse Events that is active but no longer recruiting, run by Columbia University. The registered enrollment target is 8 participants, below the 193-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (96% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT04375228, a Phase 2 study of Advanced Solid Tumor and Immune Related Adverse Events, is active but no longer recruiting, sponsored by Columbia University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to examine how effective rituximab or tocilizumab are in treating side effects for people who are receiving immunotherapy treatment requiring prolonged steroid use. Immune-related side effects are caused by the activation of the immune system. Because rituximab and tocilizumab have been shown to effectively in treating other diseased that involve immune system activation, this study seeks to evaluate how effective they will be in treating immune-related side effects in people receiving immunotherapy treatment for cancer.
Conditions Studied
Interventions
- DRUG Rituximab
- DRUG Tocilizumab
Study Locations (3)
New York
- Memorial Sloan Kettering Cancer Center - New York
- Columbia University Irving Medical Center, Herbert Irving Comprehensive Cancer Center - New York
Maryland
- Johns Hopkins - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2020-09-25 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04375228
The ClinicalTrials.gov registry entry for NCT04375228 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 193-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (96% lower). The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Advanced Solid Tumor appearing as the primary indexed condition, and to 2 interventions - of which Rituximab is the first listed.
NCT04375228 reports 3 study locations spanning 2 distinct geographic areas - top geographies include New York, Maryland.
Frequently Asked Questions
What is clinical trial NCT04375228 about?
NCT04375228 is a clinical study titled "Study of Rituximab or Tocilizumab for Patients With Steroid-Dependent Immune-Related Adverse Events (irAEs)". The purpose of this study is to examine how effective rituximab or tocilizumab are in treating side effects for people who are receiving immunotherapy treatment requiring prolonged steroid use. Immune-related side effects are caused by the activation of the immune system. Because rituximab and toci...
What is the current status of trial NCT04375228?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2020-09-25. Estimated completion is 2026-12.
What conditions does trial NCT04375228 study?
This clinical trial studies the following conditions: Advanced Solid Tumor, Immune Related Adverse Events.
What interventions are being tested in trial NCT04375228?
The interventions under investigation include: Rituximab (DRUG), Tocilizumab (DRUG).
Who is sponsoring clinical trial NCT04375228?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04375228 being conducted?
This trial has 3 study locations across Maryland, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)
RECRUITING · Phase 2
-
A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors
RECRUITING · Phase 2
-
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 2
-
A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations
ACTIVE NOT RECRUITING · Phase 2
-
Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors
COMPLETED · Phase 2
-
PM14 Administered Intravenously to Patients with Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.